Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA, Uninvited To Congress’ PCAST Hearing, Blogs Its Accomplishments

Executive Summary

Woodcock says “critical challenges” remain on implementing recommendations of President’s Council, but timing of statement could be signal to Congress: be careful what else you put on our plates.

You may also be interested in...



Drug Approval Reforms Ineffective Without Payer Reforms, Tunis Argues

Granting payers more conditional coverage authority may be necessary for legislation to succeed at accelerating biomedical innovation, the former CMS CMO argues, but industry may not be on board.

Congress Dives Into Biomedical Innovation: Will It Drown In A Deep Sea Of Competing Needs?

House Energy and Commerce committee says it’s committed to a bill to accelerate U.S. biomedical innovation before the next FDA user fee cycle, but the wide scope of needs and stakeholders may make crafting legislation challenging – never mind getting it passed.

Novartis’ Zykadia Sets New “Breakthrough” Speed Record For NME Review

FDA grants accelerated approval to ceritinib following a four-month review. The ALK inhibitor is indicated for non-small cell lung cancer patients who have progressed on or are intolerant of Pfizer’s Xalkori.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS056138

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel